Ensysce Biosciences (ENSC) investor relations material

Acquisition and financing overview

• Completed acquisition of Cy Biopharma, integrating its team and pipeline.

• Secured up to $77 million in financing, including $21.5 million private placement and $17.1 million in Cy Biopharma cash, with an additional $38.6 million contingent on clinical milestones.

• Financing led by Ally Bridge Group with participation from major institutional investors.

• Pro forma cash expected to fund operations into late 2027, with potential for further funding through 2028.

Strategic rationale and integration

• Acquisition followed a thorough evaluation of strategic alternatives to maximize shareholder value.

• Synergies identified between the two companies, especially in advancing CY200 for CRPS.

• Cy Biopharma leadership, including CEO James Morrison and CMO Richard Langford, join the combined company.

CY200 program and clinical development

• CY200 is a botanical psilocybin extract targeting complex regional pain syndrome (CRPS), with FDA Orphan Drug Designation.

• Designed as a neuroplastogenic therapy to address underlying neurobiology of CRPS, aiming for durable benefit.

• Phase II trial to assess efficacy, safety, and tolerability in CRPS type one, with top-line data as a key milestone.

• Financing proceeds primarily allocated to advance CY200 through clinical milestones and prepare for registrational development.